Air Street Capital

What they fund

Air Street Capital funds early-stage AI-first companies, investing as early as possible to iterate through product, market, and technology strategy from day 0 [1]. They target businesses where AI is the central value proposition, spanning both technology and life science sectors [1]. The firm is interested in full-stack solutions, particularly in biology, where value accrues from owning the entire stack from data to application [2]. Investments are made in companies aiming to create enduring impact on their markets, with a long-horizon vision [1].

Investment thesis

Air Street Capital operates as a venture capital firm explicitly dedicated to backing AI-first companies, with a mandate to invest as early as possible to iterate through product, market, and technology strategy from day 0 or day 1 [1]. The firm prioritizes businesses where artificial intelligence serves as the central value proposition, focusing on enduring companies that make a lasting impact on their markets rather than seeking quick flips [1]. This long-horizon vision is applied across both technology and life science sectors, emphasizing full-stack solutions and empirical computation in fields like biological imaging [2]. The firm's approach is deeply rooted in the belief that AI-first scientific exploration leverages software-defined means of solution space exploration to supercharge the pace of scientific problem-solving [2].

Credibility: The firm's homepage explicitly outlines its AI-first mandate, early-stage iteration philosophy, and focus on enduring impact [1]. The inclusion of life sciences and full-stack biology solutions is detailed in Nathan Benaich's published analysis on AI-first biology [2].

Value add

Air Street Capital offers deep domain expertise in AI and life sciences, leveraging the founder's background in computational and experimental cancer research [3]. They provide access to a global community of entrepreneurs and researchers through initiatives like The Research and Applied AI Summit (RAAIS) and the State of AI Report [3]. The firm also supports open source projects, research, and education through grants [3].

Fit verdict: Ideal for founders in AI-first technology and life sciences seeking early-stage capital and deep domain expertise in AI-driven scientific exploration.

Founder diligence script:

• How does Air Street Capital's focus on full-stack solutions in biology align with our product roadmap?
• What specific resources from the RAAIS community and State of AI Report can we leverage for go-to-market strategy?
• How does the firm's grant program for open source projects support our development efforts?
• What is the expected timeline for follow-on investments given the firm's early-stage iteration philosophy?

Portfolio focus

The firm's portfolio clusters around AI-first technology and life science companies, including those leveraging deep learning for biological image analysis and full-stack pharmaceutical solutions [2]. Specific portfolio companies are not named in the provided documents, but the focus is on startups building full-stack solutions in biology and AI-driven scientific exploration [2].

Notable investments & exits

• ClipDrop — Acquired by Stability AI (and Jasper) in 2023; a computer vision/image editing company [3].
• Fern Labs — Acquired by Poolside in 2025; an AI agents company [3].
• Gourmey — Exited in 2025; a cell-based meat company [3].
• Adept — Acquired by Amazon; an AI agents company [3].
• Allcyte — Acquired by Exscientia; a diagnostics company [3].
• Anagenex — Acquired by TCG portco; an AI+DELs (Drug Discovery) company [3].
• Athenian — Acquired by Linux; a software engineering metrics company [3].
• Graphcore — Acquired by SoftBank; an AI semiconductors company [3].
• Jukedeck — Acquired by ByteDance; an AI music company [3].
• Mapillary — Acquired by Facebook; a mapping company [3].
• Niantic — Acquired by Scopely; a real-world games company [3].
• Ravelin — Acquired by Worldpay; a fraud prevention company [3].
• Valence Discovery — Acquired by Recursion; a pharma company [3].
• Exscientia — Publicly traded on NASDAQ (EXAI); a pharma company [3].
• Recursion — Publicly traded on NASDAQ (RXRX); a pharma company [3].
• Epoch III Portfolio — Includes STARK Defence, Alta Ares, Macrodata, Onodrim, Unannounced (Ambient AI), Perceptic, Synthesia, and Black Forest Labs [3].
• Epoch II Portfolio — Includes Kradle, Clove, General Reasoning, GTV, Delfa, Polar Mist, Studio Atelico, Patina Systems, Interloom, Odyssey, Delian AI, Sereact, Samaya AI, and Profluent [3].
• Epoch I Portfolio — Includes CellVoyant, Coram AI, Gandeeva, Hedera, Intenseye, LabGenius, Mission Barns, Modern Intelligence, poolside, V7, ZOE, Andela, Automata, Chroma, Contextual.ai, Crusoe, ElevenLabs, Enveda, Lambda, Muon Space, Ndea, Numerai, Optimal, PolyAI, Flow Engineering, Thought Machine, Tractable, Starship, Stripe, Wayve, and Synthesia [3].

Strategic implications

Air Street Capital's explicit AI-first mandate and early-stage focus position it as a key player in the nascent AI-first life sciences sector, where full-stack solutions are critical. The firm's community-driven approach (RAAIS, State of AI Report) creates a powerful network effect, attracting top-tier AI talent and startups, which can lead to deal flow advantages. The lack of disclosed check sizes and portfolio counts suggests a concentrated, high-conviction strategy, which may limit diversification but increase impact per investment.

Where they could go further

Air Street Capital could enhance its value proposition by formalizing a co-investment syndicate with other early-stage AI VCs to increase deal size capacity and share risk. The firm should leverage its State of AI Report and RAAIS platform to create a dedicated AI-first life sciences accelerator, providing structured mentorship and resources to portfolio companies. Expanding geographic focus to include emerging AI hubs in Asia could diversify deal flow and tap into new markets for AI-first solutions.